Skip to main content

Dulaglutide News

FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions

ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...

Dulaglutide Cuts Weight Gain After Smoking Cessation

FRIDAY, Dec. 22, 2023 – Dulaglutide cuts post-smoking cessation weight gain in men and women, according to a study published online Dec. 19 in BMJ Nutrition, Prevention & Health. Fabienne Baur, ...

Racial, Ethnic Differences Seen for Benefits of Antihyperglycemic Agents

THURSDAY, Sept. 28, 2023 – There are racial/ethnic differences in the cardiorenal effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Cardiovascular Risk Reduction, Diabetes, Type 2, Weight Loss (Obesity / Overweight)

Related drug support groups

Trulicity

Dulaglutide patient information at Drugs.com